ascopubs.org

Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Literature searches were conducted in MEDLINE (via PubMed) and EMBASE to identify studies published between January ...
ascopubs.org

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study

To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal ...
Forbes

A Deeper Look at Anti-PD-1/PD-L1 Checkpoint Inhibitors for Cancer

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Medscape

Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC?

First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients ...